Sai Life Sciences Limited (SAILIFE) announced its financial results for the year ended 31 March 2025, reporting a strong performance driven by growth in both CDMO and CRO segments.
Key highlights for FY25:
- Revenue from operations grew by 16% to ₹1,695 crore, compared to ₹1,465 crore in FY24.
- EBITDA increased to ₹425 crore, with the EBITDA margin expanding to 25%, up from 20% in FY24.
- Profit After Tax (PAT) surged by 105% to ₹170 crore in FY25, compared to ₹83 crore in FY24.
- The increase in PAT was supported by lower finance costs and operating leverage.
- The company completed a planned ₹720 crore debt repayment, significantly strengthening the balance sheet and expected to result in lower interest costs from FY26.
- Capex for the year stood at ₹408 crore, focused on enhancing manufacturing footprint and expanding discovery capabilities.
Segmental Performance (FY25):
- CDMO contributed 63% to the total revenue.
- CRO contributed 37% to the total revenue.
- Both segments demonstrated growth momentum.
Management Commentary:
- Mr. Krishna Kanumuri, MD & CEO, stated, "We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value... One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation." He added, "As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders."
- Mr. Siva Chittor, CFO, commented, "We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by lower finance costs and operating leverage. With the completion of our planned ₹720 Cr debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26."
The company highlighted its focus on investing in technology, infrastructure, and talent and its position to tap into new growth opportunities with India emerging as a strategic hub in global drug development.